Literature DB >> 10677041

Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice.

Y Zhu1, M A King, A G Schuller, J F Nitsche, M Reidl, R P Elde, E Unterwald, G W Pasternak, J E Pintar.   

Abstract

Gene targeting was used to delete exon 2 of mouse DOR-1, which encodes the delta opioid receptor. Essentially all 3H-[D-Pen2,D-Pen5]enkephalin (3H-DPDPE) and 3H-[D-Ala2,D-Glu4]deltorphin (3H-deltorphin-2) binding is absent from mutant mice, demonstrating that DOR-1 encodes both delta1 and delta2 receptor subtypes. Homozygous mutant mice display markedly reduced spinal delta analgesia, but peptide delta agonists retain supraspinal analgesic potency that is only partially antagonized by naltrindole. Retained DPDPE analgesia is also demonstrated upon formalin testing, while the nonpeptide delta agonist BW373U69 exhibits enhanced activity in DOR-1 mutant mice. Together, these findings suggest the existence of a second delta-like analgesic system. Finally, DOR-1 mutant mice do not develop analgesic tolerance to morphine, genetically demonstrating a central role for DOR-1 in this process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10677041     DOI: 10.1016/s0896-6273(00)80836-3

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  158 in total

1.  Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence.

Authors:  H Ueda; M Inoue; H Takeshima; Y Iwasawa
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Heterodimerization of mu and delta opioid receptors: A role in opiate synergy.

Authors:  I Gomes; B A Jordan; A Gupta; N Trapaidze; V Nagy; L A Devi
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

3.  Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.

Authors:  A Alt; M J Clark; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

4.  Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.

Authors:  Shu-Husan Chou; Jen-Hsin Kao; Pao-Luh Tao; Ping-Yee Law; Horace H Loh
Journal:  Synapse       Date:  2012-03-31       Impact factor: 2.562

5.  Selective reward deficit in mice lacking beta-endorphin and enkephalin.

Authors:  Michael D Hayward; John E Pintar; Malcolm J Low
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

6.  A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.

Authors:  Ivone Gomes; Achla Gupta; Julija Filipovska; Hazel H Szeto; John E Pintar; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

7.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

8.  Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands.

Authors:  Michael A Ansonoff; Philip S Portoghese; John E Pintar
Journal:  Psychopharmacology (Berl)       Date:  2010-03-24       Impact factor: 4.530

9.  Intrathecal delivery of a mutant micro-opioid receptor activated by naloxone as a possible antinociceptive paradigm.

Authors:  J H Kao; S L Chen; H I Ma; P Y Law; P L Tao; H H Loh
Journal:  J Pharmacol Exp Ther       Date:  2010-06-16       Impact factor: 4.030

Review 10.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.